초록 ▼

The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic

The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.

대표청구항 ▼

1. An immunogenic S. agalactiae protein in substantially pure form comprising a fragment of 100 or more consecutive amino acids from the amino acid sequence SEQ ID NO:3746, wherein the protein binds to specific antibodies raised against an S. agalactiae protein comprising the amino acid sequence SEQ

1. An immunogenic S. agalactiae protein in substantially pure form comprising a fragment of 100 or more consecutive amino acids from the amino acid sequence SEQ ID NO:3746, wherein the protein binds to specific antibodies raised against an S. agalactiae protein comprising the amino acid sequence SEQ ID NO:3746, wherein the specific antibodies do not bind to unrelated antigens, and wherein the immunogenic S. agalactiae protein is an isolated protein or a recombinant protein. 2. The immunogenic S. agalactiae protein of claim 1 which is the isolated protein. 3. The immunogenic S. agalactiae protein of claim 1 which is the recombinant protein. 4. A composition comprising: an immunogenic S. agalactiae protein in substantially pure form comprising a fragment of 100 or more consecutive amino acids from the amino acid sequence SEQ ID NO:3746, wherein the protein binds to specific antibodies raised against an S. agalactiae protein comprising the amino acid sequence SEQ ID NO:3746, wherein the specific antibodies do not bind to unrelated antigens; andan adjuvant. 5. The composition of claim 4 which comprises a pharmaceutically acceptable carrier. 6. The composition of claim 4, wherein the immunogenic S. agalactiae protein is a recombinant protein. 7. The composition of claim 6, further comprising a pharmaceutically acceptable carrier. 8. The composition of claim 4, wherein the adjuvant comprises an aluminium salt. 9. The composition of claim 8 wherein the aluminium salt is alum. 10. The composition of claim 4, wherein the adjuvant comprises squalene, polyoxyethylene sorbitan monooleate, and sorbitan trioleate. 11. The composition of claim 5, wherein the adjuvant comprises an aluminium salt. 12. The composition of claim 11 wherein the aluminium salt is alum. 13. The composition of claim 5, wherein the adjuvant comprises squalene, polyoxyethylene sorbitan monooleate, and sorbitan trioleate. 14. The composition of claim 4, wherein the immunogenic S. agalactiae protein is an isolated protein. 15. The composition of claim 6, wherein the adjuvant comprises an aluminium salt. 16. The composition of claim 15, wherein the aluminium salt is alum. 17. The composition of claim 6, wherein the adjuvant comprises squalene, polyoxyethylene sorbitan monooleate, and sorbitan trioleate. 18. The composition of claim 14, wherein the adjuvant comprises an aluminium salt. 19. The composition of claim 18, wherein the aluminium salt is alum. 20. The composition of claim 14, wherein the adjuvant comprises squalene, polyoxyethylene sorbitan monooleate, and sorbitan trioleate.